Header Logo

Connection

KAREN RABIN to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Back to Details
This is a "connection" page, showing publications KAREN RABIN has written about Precursor Cell Lymphoblastic Leukemia-Lymphoma.
KAREN RABIN
Connection Strength
11.664
Precursor Cell Lymphoblastic Leukemia-Lymphoma
  1. Interplay between Genetic Ancestry, Self-reported Race and Ethnicity, and Clinical Factors in Pediatric Acute Lymphoblastic Leukemia: A REDIAL Consortium Report. Cancer Epidemiol Biomarkers Prev. 2026 May 01; 35(5):710-717.
    View in: PubMed
    Score: 0.580
  2. Management of Down Syndrome-Associated Leukemias: A Review. JAMA Oncol. 2023 09 01; 9(9):1283-1290.
    View in: PubMed
    Score: 0.483
  3. Insights into the genomics of iAMP21-ALL. Blood. 2023 08 24; 142(8):682-684.
    View in: PubMed
    Score: 0.482
  4. Genetic Ancestry and Childhood Acute Lymphoblastic Leukemia Subtypes and Outcomes in the Genomic Era. JAMA Oncol. 2022 03 01; 8(3):342-343.
    View in: PubMed
    Score: 0.435
  5. Risk stratification for Down syndrome and acute lymphocytic leukaemia: one size does not fit all. Lancet Haematol. 2021 Oct; 8(10):e673-e675.
    View in: PubMed
    Score: 0.423
  6. Enhancer polymorphisms at the IKZF1 susceptibility locus for acute lymphoblastic leukemia impact B-cell proliferation and differentiation in both Down syndrome and non-Down syndrome genetic backgrounds. PLoS One. 2021; 16(1):e0244863.
    View in: PubMed
    Score: 0.402
  7. Optimizing Targeted Therapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. JAMA Oncol. 2020 03 01; 6(3):333-334.
    View in: PubMed
    Score: 0.379
  8. Need for new thinking: Treatment of relapsed leukemia in children with Down syndrome. Pediatr Blood Cancer. 2019 06; 66(6):e27644.
    View in: PubMed
    Score: 0.352
  9. First do no harm: infectious deaths in pediatric ALL. Blood. 2014 Aug 14; 124(7):987-9.
    View in: PubMed
    Score: 0.258
  10. Reply to "Peripheral blood lymphocyte recovery and overall survival in pediatric acute lymphoblastic leukemia". Pediatr Blood Cancer. 2014 Jan; 61(1):180.
    View in: PubMed
    Score: 0.241
  11. The adolescent and young adult with cancer: state of the art-- acute leukemias. Curr Oncol Rep. 2013 Aug; 15(4):317-24.
    View in: PubMed
    Score: 0.240
  12. Attacking remaining challenges in childhood leukemia. N Engl J Med. 2012 Apr 12; 366(15):1445-6.
    View in: PubMed
    Score: 0.219
  13. Myelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Apr; 58(4):633-5.
    View in: PubMed
    Score: 0.213
  14. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Sep; 59(3):468-74.
    View in: PubMed
    Score: 0.213
  15. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia. 2011 Oct; 25(10):1555-63.
    View in: PubMed
    Score: 0.207
  16. Management strategies in acute lymphoblastic leukemia. Oncology (Williston Park). 2011 Apr 15; 25(4):328-35.
    View in: PubMed
    Score: 0.205
  17. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009 Nov; 41(11):1243-6.
    View in: PubMed
    Score: 0.185
  18. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009 Mar; 144(6):930-2.
    View in: PubMed
    Score: 0.174
  19. Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia. Leuk Res. 2009 Feb; 33(2):336-9.
    View in: PubMed
    Score: 0.170
  20. Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008 Aug; 51(2):171-7.
    View in: PubMed
    Score: 0.170
  21. Personalized care of pediatric cancer patients. Nestle Nutr Workshop Ser Pediatr Program. 2008; 62:173-85; discussion 185-8.
    View in: PubMed
    Score: 0.163
  22. Racial, Ethnic, and Neighborhood Disparities in Acute Kidney Injury in Pediatric Acute Leukemia. Cancer Med. 2026 May; 15(5):e71937.
    View in: PubMed
    Score: 0.145
  23. Lipidomic profiles associated with treatment related hepatotoxicity in children with acute lymphoblastic leukemia. Support Care Cancer. 2026 Feb 17; 34(3):209.
    View in: PubMed
    Score: 0.143
  24. Structural birth defects and leukemia risk in children with Down syndrome. Sci Rep. 2025 Dec 11; 16(1):1741.
    View in: PubMed
    Score: 0.141
  25. An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy. Blood Adv. 2025 Nov 25; 9(22):5802-5810.
    View in: PubMed
    Score: 0.141
  26. The impact of Indigenous American-like ancestry on the risk of acute lymphoblastic leukemia in Hispanic/Latino children. HGG Adv. 2026 Jan 15; 7(1):100534.
    View in: PubMed
    Score: 0.140
  27. Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia. Oncologist. 2025 Jun 04; 30(6).
    View in: PubMed
    Score: 0.136
  28. Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
    View in: PubMed
    Score: 0.132
  29. Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia. 2025 Mar; 39(3):555-567.
    View in: PubMed
    Score: 0.132
  30. Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management. Pediatr Blood Cancer. 2025 Jan; 72(1):e31377.
    View in: PubMed
    Score: 0.130
  31. Cerebral Sinus Venous Thrombosis in Pediatric Acute Lymphoblastic Leukemia: Incidence, Clinical Characteristics, and Long-term Neurologic Outcomes. J Child Neurol. 2024 Nov; 39(13-14):494-499.
    View in: PubMed
    Score: 0.130
  32. Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3491-3503.
    View in: PubMed
    Score: 0.129
  33. Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatr Blood Cancer. 2024 Sep; 71(9):e31169.
    View in: PubMed
    Score: 0.128
  34. Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Leukemia. 2024 04; 38(4):720-728.
    View in: PubMed
    Score: 0.125
  35. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood. 2023 12 14; 142(24):2069-2078.
    View in: PubMed
    Score: 0.123
  36. Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemia. Pediatr Blood Cancer. 2024 Jan; 71(1):e30726.
    View in: PubMed
    Score: 0.122
  37. Down syndrome and leukemia: from basic mechanisms to clinical advances. Haematologica. 2023 10 01; 108(10):2570-2581.
    View in: PubMed
    Score: 0.121
  38. Flow cytometric assessment of leukemia-associated monocytes in childhood B-cell acute lymphoblastic leukemia outcome. Blood Adv. 2023 08 08; 7(15):3928-3931.
    View in: PubMed
    Score: 0.120
  39. Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30585.
    View in: PubMed
    Score: 0.120
  40. Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. Blood. 2023 07 13; 142(2):172-184.
    View in: PubMed
    Score: 0.120
  41. Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia. Haematologica. 2023 03 01; 108(3):900-904.
    View in: PubMed
    Score: 0.117
  42. Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacotherapy. 2023 03; 43(3):205-214.
    View in: PubMed
    Score: 0.116
  43. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. Lancet Haematol. 2023 Feb; 10(2):e129-e141.
    View in: PubMed
    Score: 0.116
  44. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate. Cancer. 2023 04 15; 129(8):1287-1294.
    View in: PubMed
    Score: 0.116
  45. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2022 11; 69(11):e29937.
    View in: PubMed
    Score: 0.113
  46. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022 09; 54(9):1376-1389.
    View in: PubMed
    Score: 0.113
  47. Epigenome-wide association study of acute lymphoblastic leukemia in children with Down syndrome. Blood Adv. 2022 07 26; 6(14):4132-4136.
    View in: PubMed
    Score: 0.112
  48. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. Lancet Haematol. 2022 Sep; 9(9):e678-e688.
    View in: PubMed
    Score: 0.112
  49. A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica. 2022 05 01; 107(5):1185-1188.
    View in: PubMed
    Score: 0.110
  50. CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome. Exp Hematol. 2022 06; 110:34-38.
    View in: PubMed
    Score: 0.109
  51. Residence in a Latinx enclave and end-induction minimal residual disease positivity among children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2022 Oct; 39(7):650-657.
    View in: PubMed
    Score: 0.109
  52. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022 05 01; 128(9):1863-1870.
    View in: PubMed
    Score: 0.109
  53. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol. 2021 Oct 01; 7(10):1521-1528.
    View in: PubMed
    Score: 0.106
  54. Converging genetic and epigenetic drivers of paediatric acute lymphoblastic leukaemia identified by an information-theoretic analysis. Nat Biomed Eng. 2021 04; 5(4):360-376.
    View in: PubMed
    Score: 0.102
  55. Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene. Pediatr Blood Cancer. 2021 08; 68(8):e29036.
    View in: PubMed
    Score: 0.102
  56. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 04; 68(4):e28929.
    View in: PubMed
    Score: 0.101
  57. Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. Blood. 2021 01 21; 137(3):364-373.
    View in: PubMed
    Score: 0.101
  58. Area deprivation is associated with poorer overall survival in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020 09; 67(9):e28525.
    View in: PubMed
    Score: 0.097
  59. Six Candidate miRNAs Associated With Early Relapse in Pediatric B-Cell Acute Lymphoblastic Leukemia. Anticancer Res. 2020 Jun; 40(6):3147-3153.
    View in: PubMed
    Score: 0.096
  60. Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. Pediatr Blood Cancer. 2021 09; 68(9):e28315.
    View in: PubMed
    Score: 0.096
  61. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020 07; 34(7):1741-1750.
    View in: PubMed
    Score: 0.094
  62. Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood. 2019 10 10; 134(15):1227-1237.
    View in: PubMed
    Score: 0.092
  63. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. Blood Adv. 2019 06 11; 3(11):1647-1656.
    View in: PubMed
    Score: 0.090
  64. Maternal Residential Proximity to Major Roadways and the Risk of Childhood Acute Leukemia: A Population-Based Case-Control Study in Texas, 1995-2011. Int J Environ Res Public Health. 2019 06 07; 16(11).
    View in: PubMed
    Score: 0.090
  65. Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia. PLoS One. 2018; 13(5):e0197408.
    View in: PubMed
    Score: 0.084
  66. Family-based exome-wide association study of childhood acute lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility. PLoS One. 2017; 12(8):e0180488.
    View in: PubMed
    Score: 0.079
  67. Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics. Cancer. 2016 Dec 01; 122(23):3697-3704.
    View in: PubMed
    Score: 0.074
  68. Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients. Am J Clin Pathol. 2015 Aug; 144(2):263-70.
    View in: PubMed
    Score: 0.069
  69. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014 Jan 02; 123(1):70-7.
    View in: PubMed
    Score: 0.061
  70. Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. Clin Cancer Res. 2013 Sep 15; 19(18):5079-91.
    View in: PubMed
    Score: 0.060
  71. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011 Aug; 25(8):1365-8.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.